Multiple Myeloma Management 17+
Med Learning Group
Designed for iPad
-
- Free
Screenshots
Description
This program discusses relapsed/refractory multiple myeloma and role of BCMA therapies
Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma. Recognizing the mechanism of these agents as well as preliminary efficacy data is important in considering clinical trials and implementing approved bispecific antibodies in the management of multiple myeloma.
App Privacy
The developer, Med Learning Group, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy.
Data Not Collected
The developer does not collect any data from this app.
Privacy practices may vary based on, for example, the features you use or your age. Learn More
Information
- Provider
- UMA MLG, LLC
- Size
- 94.3 MB
- Category
- Medical
- Compatibility
-
- iPhone
- Requires iOS 11.0 or later.
- iPad
- Requires iPadOS 11.0 or later.
- iPod touch
- Requires iOS 11.0 or later.
- Mac
- Requires macOS 11.0 or later and a Mac with Apple M1 chip or later.
- Languages
-
English
- Age Rating
- 17+ Frequent/Intense Medical/Treatment Information
- Copyright
- © 2023 UMA MLG, LLC
- Price
- Free